1 / 7

Hemophilia Market Overview Till 2026

According to the current analysis of Reports and Data, the global Hemophilia market was valued at USD 11.10 Billion in 2018 and is expected to reach USD 16.84 Billion by the year 2026, at a CAGR of 5.4 percent.

thomasburnsrnd
Download Presentation

Hemophilia Market Overview Till 2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hemophilia Market To Reach USD 16.84 Billion By 2026 www.reportsanddata.com sales@reportsanddata.com

  2. Market Summary Rising incidences of hemophilia, increasing awareness, technological advancements,  strategic developments by key market players such as partnerships and mergers and acquisitions, favorable research and developments are the key factors propelling the hemophilia market. Market Size – USD 11.10 Billion in 2018, Market Growth - CAGR of 5.4%, Market Trends – Product launches and technological advancements. According to the current analysis of Reports and Data, the global Hemophilia market was valued at USD 11.10 Billion in 2018 and is expected to reach USD 16.84 Billion by the year 2026, at a CAGR of 5.4 percent.

  3. Our Approach Market Summary Hemophilia is a rare genetic disorder in which blood doesn't clot normally because it lacks sufficient blood-clotting proteins known as clotting factors. Among the types of disorders, type A is anticipated to be multiple times more predominant than type B. The global market for hemophilia drugs is growing significantly, owing to the increasing number of hemophilic patients globally. Hemophilia medications are turning out to be one of the essential medicinal products to confine the loss of blood as there is no exact treatment accessible to treat this disorder. Strategies such as geographical expansion by the key market players and new product development are expected to have the most impact on the Hemophilia market. Rising prevalence of the disorder, a significant focus of key market players on the development of gene therapy mechanism, increasing awareness about the disorder, and favorable regulatory scenario, are some of the key factors that support the market growth in the industry. However, lack of availability of medicine and high cost of treatment are the factors that limit the market growth over the globe during 2019-2026. Request for a sample of this research report @ https://www.reportsanddata.com/sample-enquiry-form/2249Further key findings from the report suggest

  4. Our Approach Market Summary Launch of products for hemophilia treatment is expected to support the market growth during the coming years. For instance, in May 2018 FDA approved Roche’s Hemlibra for treatment of hemophilia with or without inhibitors. North America dominates the regional hemophilia market and held around 48% market share in 2018. Hemophilia B is projected to be the fastest growing segment at a CAGR of 5.7%. However, low availability of treatment for the segment is a major challenge for the market growth for this segment. Asia Pacific is expected to show a high growth rate in the hemophilic market and will grow at a CAGR of 6% Recombinant coagulation factor concentrate and plasma coagulation factor concentrate are the common options to treat hemophilia and are expected to take up an important position in the global hemophilia market owing to increased prevalence of the von Willebrand Disease. On-demand treatment segment is expected to grow at a CAGR of 5.6%. To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/hemophilia-market

  5. Our Approach Market Summary Key participants include Shire (Takeda), Bayer Healthcare, CSL Behring, Novo Nordisk, Sanofi, Pfizer Inc., among others. For the purpose of this report, Reports and Data has segmented the Hemophilia market on the basis of type, product type, treatment type, therapy type, and region: Type (Revenue, USD Million; 2016–2026) Hemophilia A Hemophilia B Hemophilia C Others Product (Revenue, USD Million; 2016–2026) Plasma derived coagulation factor concentrates Recombinant coagulation factor concentrates            Desmopressin Antifibrinolytic agents Others

  6. Our Approach Market Summary Treatment Type (Revenue, USD Million; 2016–2026) Prophylactic On-Demand Therapy Type (Revenue, USD Million; 2016–2026) Replacement Therapy Immune Tolerance Induction Therapy Gene Therapy Order Now: https://www.reportsanddata.com/checkout-form/2249 Regional Outlook (Volume, Kilo Tons and Revenue, USD Billion; 2016-2026) North America Europe Asia Pacific MEA Latin America

  7. Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Contact Us: John Watson Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com About Us Our Approach About Us

More Related